A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
about
PI3K/Akt/mTOR inhibitors in breast cancerSurgery in the era of the 'omics revolutionMolecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway BlockadeA Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium ReportGeneration and screening of monoclonal antibodies for immunoPET imaging of IGF1R in prostate cancer.Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.Accounting for the delay in the transition from acute to chronic pain: axonal and nuclear mechanismsThe combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trialThe role of the insulin-like growth factor-1 system in breast cancerCalycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study.STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibodySelective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer: A Retrospective Cohort Analysis.Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications.Type I insulin-like growth factor receptor signaling in hematological malignancies.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.Targeting the Breast Cancer Kinome.Safety of mTOR inhibitors in breast cancer.Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin.Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine TherapyReceptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes.Targeted Therapies Against Growth Factor Signaling in Breast Cancer.Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
P2860
Q26771394-B1A1E85E-CE98-43EB-8AC2-1C1D3E9157F3Q26852061-AAAA9C6C-DEFA-46A4-9E6B-4720F6D5389BQ28088432-4ACAFD05-CAFC-4467-ACA3-000F802C76D3Q33419115-779F7520-666C-4EB9-A99D-BD2DFED407A0Q34293602-BB66F522-2EC0-42D8-9B88-F55FD130EFDAQ34515619-3BBD3E20-8607-4E19-9469-D3DC3852C2EDQ34946158-9F9D7A28-17DC-4D72-AD0A-90ED8B341A03Q34984126-5ACF097B-FBF9-4FFC-8425-68927B78033BQ35105295-82972087-0B23-450C-BC22-A320FF32654BQ35117885-AEB94588-3417-4007-B0F7-A7141661F07CQ35820533-7201477A-D805-4122-A24A-DA1384A5822FQ35850208-8C0027AB-F6A1-4605-872C-67FAD261B64EQ36139739-CF7389A1-EA47-4122-90E6-16A31A29E2E3Q36169762-DE9B5EB5-615F-404C-ADB3-421EBE24314AQ36195386-EAD5D205-1FBB-42C3-889E-FB409390BB92Q36433403-4A7EF01F-F64B-45CE-8B48-E28997A55AC8Q36788273-7377FE76-9788-4B6C-839A-5787DD791312Q37702186-49F5B865-E19D-4514-9881-A550EEF0FDAEQ38242086-C30FB825-A9EA-445D-8FDA-5F18C8AC09A2Q38393041-9A72A360-DBA3-4706-A48A-B93071AB4CA4Q38836110-5D3CC411-8377-4C33-99BF-DEC2CD6537A4Q38841039-52C36F25-6AB7-478B-8455-0DCD3882E553Q39044596-925E14BB-3AB8-47EA-81E2-1E4CE2D86367Q41302136-A3793640-FB0B-49CF-9B12-413BABA6DA29Q46237958-636BDFD3-7884-4E00-BE5D-F3F48F41AE00Q47143930-B6EC3A85-9E74-452B-B877-42E7386C6111Q47559665-322A6E38-29A0-461E-9262-00D43CA1B978Q49723815-CB170613-B556-4E32-B7C4-A3B1DEAB3633Q53586091-BFB8E6AE-FFF9-40E8-93EF-806A21E9B7B0
P2860
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase I trial of the IGF-1R ...... with metastatic breast cancer.
@ast
A phase I trial of the IGF-1R ...... with metastatic breast cancer.
@en
type
label
A phase I trial of the IGF-1R ...... with metastatic breast cancer.
@ast
A phase I trial of the IGF-1R ...... with metastatic breast cancer.
@en
prefLabel
A phase I trial of the IGF-1R ...... with metastatic breast cancer.
@ast
A phase I trial of the IGF-1R ...... with metastatic breast cancer.
@en
P2093
P2860
P1476
A phase I trial of the IGF-1R ...... with metastatic breast cancer.
@en
P2093
Charles Erlichman
Cynthia X Ma
Gini F Fleming
Helen X Chen
Matthew Goetz
Matthew J Ellis
Paul Haluska
Rita Nanda
Timothy Moynihan
Timothy Pluard
P2860
P2888
P304
P356
10.1007/S10549-013-2528-8
P407
P577
2013-04-19T00:00:00Z
P6179
1037031036